Suscribirse

Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients? - 17/09/17

Doi : 10.1016/j.amjmed.2017.05.026 
Marie Méan, MD a, b, ⁎ , Andreas Limacher, PhD c, Odile Stalder, MSc c, Anne Angelillo-Scherrer, MD d, e, Lorenzo Alberio, MD f, Pierre Fontana, MD, PhD g, Hans-Jürg Beer, MD h, Nicolas Rodondi, MD, MAS a, i, Bernhard Lämmle, MD d, j, Drahomir Aujesky, MD, MSc a
a Department of General Internal Medicine, Bern University Hospital, University of Bern, Switzerland 
b Division of General Internal Medicine, Lausanne University Hospital, Switzerland 
c CTU Bern and Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland 
d University Clinic of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Switzerland 
e Department of Clinical Research, University of Bern, Switzerland 
f Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital, Switzerland 
g Division of Angiology and Haemostasis, Geneva University Hospital, Switzerland 
h Department of Internal Medicine, Cantonal Hospital of Baden, Switzerland 
i Institute of Primary Health Care, University of Bern, Switzerland 
j Center for Thrombosis und Hemostasis, University Medical Center, Mainz, Germany 

∗Requests for reprints should be addressed to Marie Méan, MD, Division of General Internal Medicine, Lausanne University Hospital, Rue du Bugnon 46, 1011 Lausanne, Switzerland.Division of General Internal MedicineLausanne University HospitalRue du Bugnon 46Lausanne1011Switzerland

Abstract

Background

The value of genetic thrombophilia testing in elderly patients with an unprovoked venous thromboembolism is unclear. We assessed whether the Factor V Leiden and the prothrombin G20210A mutation are associated with recurrent venous thromboembolism in elderly patients in a prospective multicenter cohort study.

Methods

We genotyped the Factor V Leiden and the prothrombin G20210A mutation in 354 consecutive in- and outpatients aged ≥65 years with a first unprovoked venous thromboembolism from 9 Swiss hospitals. Patients and managing physicians were blinded to testing results. The outcome was recurrent symptomatic venous thromboembolism during follow-up. We examined the association between the Factor V Leiden and the prothrombin G20210A mutation and venous thromboembolism recurrence using competing risk regression, adjusting for age, sex, and periods of anticoagulation as a time-varying covariate.

Results

Overall, 9.0% of patients had a Factor V Leiden and 3.7% had a prothrombin G20210A mutation. At 36 months of follow-up, patients with a Factor V Leiden and a prothrombin G20210A mutation had a cumulative incidence of recurrent venous thromboembolism of 12.9% (95% confidence interval [CI], 5.1%-30.8%) and 18.5% (95% CI, 4.9%-56.5%), respectively, compared with 16.7% (95% CI, 12.5%-22.1%) of patients without mutation (P = .91 by the log-rank test). After adjustment, neither the Factor V Leiden (sub-hazard ratio 0.98; 95% CI, 0.35-2.77) nor the prothrombin G20210A mutation (sub-hazard ratio 1.15; 95% CI, 0.25-5.19) was associated with recurrent venous thromboembolism.

Conclusion

Our results suggest that testing for genetic thrombophilia may not be beneficial in elderly patients with a first unprovoked venous thromboembolism.

El texto completo de este artículo está disponible en PDF.

Keywords : Elderly, Recurrent venous thromboembolism, Thrombophilia


Esquema


 Funding: The study was supported by a grant from the Swiss National Science Foundation (SNSF) (33CSCO-122659/139470).
 Conflict of Interest: The authors have no conflicts of interest.
 Authorship: Planning of the study: MM, AL, DA; Obtaining funding: H-JB, AA-S, BL, NR, DA; Data collection: H-JB, AA-S, BL, NR, DA; Statistical analyses: AL, OS; Laboratory measurements and interpretation of results: PF, LA, BL, AA-S; Drafting of the manuscript: MM, AL, DA; Intellectual review of the manuscript: H-JB, AA-S, PF, LA, BL, NR, DA. All authors had access to the data.


© 2017  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 130 - N° 10

P. 1220.e17-1220.e22 - octobre 2017 Regresar al número
Artículo precedente Artículo precedente
  • Patterns of Readmissions for Three Common Conditions Among Younger US Adults
  • Devraj Sukul, Shashank S. Sinha, Andrew M. Ryan, Michael W. Sjoding, Scott L. Hummel, Brahmajee K. Nallamothu
| Artículo siguiente Artículo siguiente
  • Diagnosing Bilateral Tarsal Tunnel Syndrome
  • Kohei Morinaga, Taro Shimizu

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.